Rai Staging System for CLL
Staging system for chronic lymphocytic leukaemia (CLL) based on clinical and haematological features. Predicts prognosis and guides treatment.
Score interpretation
Low risk. Median survival >10 years.
→ Watch and wait; no immediate treatment indicated. Monitor with regular FBC and clinical examination.
Intermediate risk. Median survival 7–9 years.
→ Watch and wait unless active disease criteria met. Consider enrolment in clinical trials.
High risk. Median survival 1.5–5 years.
→ Treatment indicated if symptomatic. Consider chemoimmunotherapy (CLL14, GAIA) or targeted therapy (BTK/BCL2 inhibitors). Haematology review.
Interpretation bands for the Rai CLL. Apply clinical judgement and local guidance.
References
- Rai KR et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.
- Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
Related
Curated clinical cross-links plus same-class fallbacks.
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Fentanyl Transdermal Patch (Elderly Chronic Pain) · Opioid Analgesic — Transdermal Patch
- Morphine Slow-Release (Elderly Chronic Pain) · Opioid Analgesic — Modified-Release Oral
- Obinutuzumab · Anti-CD20 Monoclonal Antibody — CLL / Follicular Lymphoma
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.